Journal Article

Novel Potent and Selective Dopamine D4 Receptor Piperidine Antagonists as Potential Alternatives for the Treatment of Glioblastoma

Yano, Hideaki, Matteucci, Federica, Petrelli, Riccardo, Cappellacci, Loredana, Sabato, Emanuela, Quaglia, Wilma, Vistoli, Giulio, Garland, Rian, Mammoli, Valerio, Pavletić, Pegi, Bonifazi, Alessandro, Piergentili, Alessia, Zeppa, Laura, Del Bello, Fabio, Piergentili, Alessandro, Amantini, Consuelo, Giorgioni, Gianfabio

2025

Overview

Background/Objectives: D4R antagonists have recently been suggested as potential therapeutic alternatives to the standard treatments of glioblastoma (GBM). In this study, new piperidine-based ligands, analogs of the potent and selective D4R compounds 77-LH-28-1 (7) and its 4-benzyl analog 8, were synthesized and studied to investigate the effects produced by variations in the distances between the pharmacophoric features on the D4R affinity and selectivity. Methods: All the new compounds 9–20 were evaluated for their radioligand binding affinity at D2-like receptor subtypes and the results were rationalized by docking studies and molecular dynamics (MD) simulations. The functional profiles of the most interesting derivatives were assessed at D4R Go and Gi protein and β-arrestin by BRET assay and their potential anticancer activity was determined in GBM cell lines. Results: Radioligand binding results highlighted that the derivatives bearing a terminal butyl chain showed structure–activity relationships different from those with a benzyl terminal. From functional studies performed on the best derivatives 12 and 16, the response profiles of both compounds were more robust in antagonist mode, with derivative 16 showing higher antagonist potency than 12 across all three transducers. Interestingly, 12 and 16 dose-dependently decreased the cell viability of GBM cells, inducing cell death and cell cycle arrest, promoting an increase in ROS production, causing mitochondrial dysfunction, and significantly inhibiting colony formation. Conclusions: The promising biological profiles of 12 and 16 make them new lead candidates that warrant further investigation to gain a better understanding of the mechanism behind their antitumor activity and better evaluate their potential for GBM treatment.

• Publisher: MDPI AG,MDPI
• Subject: 4-butyl- and 4-benzyl-piperidines / Alcohol / Antagonists (Biochemistry) / Brain cancer / Development and progression / docking studies / Dopamine / dopamine D4 receptors / Dopamine receptors / Drug therapy / glioblastoma / Glioblastoma multiforme / Glioma / Health aspects / Kinases / Life sciences / Ligands / Physiological aspects / potent and selective D4R antagonists / Proteins